Interim 52-week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A-MedSci.cn

Interim 52-week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A

Long, B; Fong, S; Handyside, B; Robinson, T; Day, J; Yu, H; Lau, K; Patton, K; de Hart, G; Henshaw, J; Agarwal, S; Vettermann, C; Gupta, S

JOURNAL OF HEPATOLOGY, 2022; 77 (): S540

科室
- - 订阅+
  - 更多科室
工具
服务